The Manufacturers Life Insurance Company Buys 192,988 Shares of Cencora, Inc. $COR

The Manufacturers Life Insurance Company lifted its stake in Cencora, Inc. (NYSE:COR) by 21.0% in the 1st quarter, HoldingsChannel reports. The firm owned 1,112,541 shares of the company’s stock after buying an additional 192,988 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Cencora were worth $349,494,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Kemnay Advisory Services Inc. bought a new position in Cencora in the fourth quarter worth about $25,000. Oakworth Capital Inc. bought a new stake in Cencora during the 4th quarter valued at approximately $26,000. Elyxium Wealth LLC bought a new stake in Cencora during the 4th quarter valued at approximately $27,000. Archer Investment Corp grew its holdings in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after acquiring an additional 47 shares during the period. Finally, Motiv8 Investments LLC purchased a new position in shares of Cencora during the 4th quarter worth approximately $29,000. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

COR opened at $311.42 on Tuesday. The company’s 50 day moving average is $285.51 and its 200 day moving average is $316.05. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The company has a market cap of $60.59 billion, a price-to-earnings ratio of 23.88, a PEG ratio of 1.72 and a beta of 0.58. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same period in the prior year, the company posted $4.42 earnings per share. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, equities research analysts predict that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio is 18.40%.

Cencora announced that its Board of Directors has approved a share repurchase program on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the company to buy up to 3.9% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on COR shares. Weiss Ratings cut Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 30th. Citigroup dropped their price target on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Wells Fargo & Company reduced their price target on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research note on Monday, May 11th. William Blair assumed coverage on Cencora in a report on Tuesday, April 28th. They issued a “market perform” rating for the company. Finally, Bank of America raised their price objective on Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a research report on Wednesday, June 24th. Eleven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $367.75.

Insider Buying and Selling

In related news, Director Lauren M. Tyler bought 550 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were bought at an average cost of $270.23 per share, with a total value of $148,626.50. Following the acquisition, the director owned 4,359 shares in the company, valued at $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.38% of the company’s stock.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.